Obesity drug developers Structure Therapeutics (NASDAQ:GPCR) and Metsera (NASDAQ:MTSR) recorded sharp gains alongside Eli ...

Shares of obesity drug developers were volatile this week amid good news for Eli Lilly's (LLY) drug candidate orforglipron, ...

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

Shares of up-and-coming weight loss drug developers Viking Therapeutics (NASDAQ:VKTX), Metsera (NASDAQ:MTSR), and Structure Therapeutics (NASDAQ:GPCR) traded sharply higher after Pfizer (NYSE ...

Pfizer to discontinue danuglipron weight-loss drug, but has other obesity treatments ... "second-most advanced" oral GLP-1 in development. Metsera Inc. also stands to benefit, as while its oral ...

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq ... dose four-fold higher than the weekly dose continued to lose weight, with an arithmetic mean placebo-subtracted change ...

Structure Therapeutics (GPCR) stock and Metsera (MTSR) stock soar as Eli Lilly (LLY) reports promising Phase 3 results for ...

Shares of Viking Therapeutics, Altimmune, Structure Therapeutics and Metsera — all of which have weight loss drugs in clinical testing — rose in trading Monday.